busulfan has been researched along with Lymphoma, B-Cell in 9 studies
Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For chemosensitive advanced high-risk B-cell lymphoma, the addition of (90)Y-Ibritumomab tiuxetan to a RIC regimen based on fludarabine, busulfan and antithymocyte globulin followed by allogeneic transplant is safe and highly effective." | 9.20 | 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas. ( Asselineau, J; Blaise, D; Bouabdallah, K; Bouabdallah, R; Ceballos, P; Chevalier, P; Doussau, A; Furst, S; Le Gouill, S; Milpied, N; Mohty, M; Tabrizi, R; Tournilhac, O; Vigouroux, S, 2015) |
| "For chemosensitive advanced high-risk B-cell lymphoma, the addition of (90)Y-Ibritumomab tiuxetan to a RIC regimen based on fludarabine, busulfan and antithymocyte globulin followed by allogeneic transplant is safe and highly effective." | 5.20 | 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas. ( Asselineau, J; Blaise, D; Bouabdallah, K; Bouabdallah, R; Ceballos, P; Chevalier, P; Doussau, A; Furst, S; Le Gouill, S; Milpied, N; Mohty, M; Tabrizi, R; Tournilhac, O; Vigouroux, S, 2015) |
| " We evaluated the efficacy and safety of yttrium-90-ibritumomab tiuxetan ((90)Y-ibritumomab) combined with intravenous busulfan, cyclophosphamide, and etoposide (Bu/Cy/E) followed by ASCT in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)." | 2.75 | Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. ( Choi, YH; Huh, J; Jang, G; Kang, BW; Kim, C; Kim, S; Kim, SW; Kim, WS; Lee, DH; Lee, JS; Lee, SS; Ryu, JS; Suh, C, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Takahashi, M | 1 |
| Sumitani, R | 1 |
| Hori, T | 1 |
| Murai, J | 1 |
| Kawata, S | 1 |
| Oura, M | 1 |
| Sogabe, K | 1 |
| Harada, T | 1 |
| Fujii, S | 1 |
| Miki, H | 1 |
| Kagawa, K | 1 |
| Abe, M | 1 |
| Nakamura, S | 1 |
| Bouabdallah, K | 1 |
| Furst, S | 1 |
| Asselineau, J | 1 |
| Chevalier, P | 1 |
| Tournilhac, O | 1 |
| Ceballos, P | 1 |
| Vigouroux, S | 1 |
| Tabrizi, R | 1 |
| Doussau, A | 1 |
| Bouabdallah, R | 1 |
| Mohty, M | 1 |
| Le Gouill, S | 1 |
| Blaise, D | 1 |
| Milpied, N | 1 |
| Kang, BW | 1 |
| Kim, WS | 1 |
| Kim, C | 1 |
| Jang, G | 1 |
| Lee, SS | 1 |
| Choi, YH | 1 |
| Lee, DH | 1 |
| Kim, SW | 1 |
| Kim, S | 1 |
| Ryu, JS | 1 |
| Huh, J | 1 |
| Lee, JS | 1 |
| Suh, C | 1 |
| Stewart, DA | 1 |
| Duan, Q | 1 |
| Carlson, L | 1 |
| Russell, JA | 1 |
| Bahlis, NJ | 1 |
| Duggan, P | 1 |
| Hasegawa, W | 1 |
| Voralia, M | 1 |
| Soussain, C | 2 |
| Hoang-Xuan, K | 2 |
| Levy, V | 2 |
| Smith, SD | 1 |
| Bolwell, BJ | 1 |
| Rybicki, LA | 1 |
| Brown, S | 1 |
| Dean, R | 1 |
| Kalaycio, M | 1 |
| Sobecks, R | 1 |
| Andresen, S | 1 |
| Hsi, ED | 1 |
| Pohlman, B | 1 |
| Sweetenham, JW | 1 |
| Scheid, C | 1 |
| Pettengell, R | 1 |
| Ghielmini, M | 1 |
| Radford, JA | 1 |
| Morgenstern, GR | 1 |
| Stern, PL | 1 |
| Crowther, D | 1 |
| Suzan, F | 1 |
| Cassoux, N | 1 |
| Azar, N | 1 |
| Belanger, C | 1 |
| Achour, E | 1 |
| Ribrag, V | 1 |
| Gerber, S | 1 |
| Delattre, JY | 1 |
| Leblond, V | 1 |
| Loiseau, HA | 1 |
| Hartmann, O | 1 |
| Valteau, D | 1 |
| McDowell, H | 1 |
| Brugières, L | 1 |
| Vassal, G | 1 |
| Kalifa, C | 1 |
| Patte, C | 1 |
| Lemerle, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin®) in Association With a Fludarabine Based Reduced Conditioning Regimen and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.[NCT00607854] | Phase 2 | 31 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Combining 90Y-ibritumomab Tiuxetan With High-dose Chemotherapy of BuCyE and Autologous Stem Cell Transplantation in Patients With B-cell Non-Hodgkin's Lymphoma - an Open-labeled Phase II Study[NCT00336843] | Phase 2 | 19 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| High Dose Chemotherapy and Autologous or Allogeneic Blood Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma[NCT00144092] | Phase 2 | 60 participants (Anticipated) | Interventional | 2001-05-31 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
4 trials available for busulfan and Lymphoma, B-Cell
| Article | Year |
|---|---|
90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.
Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Mo | 2010 |
A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; C | 2001 |
5 other studies available for busulfan and Lymphoma, B-Cell
| Article | Year |
|---|---|
Intravenous busulfan-based conditioning with autologous stem cell transplantation for refractory B-cell lymphoma with central nervous system involvement.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System; Combi | 2021 |
[Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2004 |
Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; | 2007 |
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; | 1995 |
High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dose-Res | 1991 |